# A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

> **NCT06419205** · PHASE2 · WITHDRAWN · sponsor: **Q32 Bio Inc.**

## Conditions studied

- IgA Nephropathy
- Lupus Nephritis (LN)
- C3 (Complement Component 3) Glomerulopathy

## Interventions

- **DRUG:** ADX-097

## Key facts

- **NCT ID:** NCT06419205
- **Lead sponsor:** Q32 Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-06-27
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** study closed prior to enrolling any patients.
- **Last updated:** 2025-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06419205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06419205, "A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06419205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*